- Sections
- C - Chimiemétallurgie
- C07K - Peptides
- C07K 16/08 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus
Détention brevets de la classe C07K 16/08
Brevets de cette classe: 1421
Historique des publications depuis 10 ans
|
80
|
86
|
110
|
99
|
108
|
127
|
117
|
123
|
106
|
36
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Regeneron Pharmaceuticals, Inc. | 4261 |
26 |
| Novartis AG | 10829 |
24 |
| Genentech, Inc. | 3983 |
19 |
| City of Hope | 994 |
19 |
| Deutsches Krebsforschungszentrum | 418 |
19 |
| The Regents of the University of California | 19943 |
17 |
| Duke University | 3067 |
16 |
| Xiamen University | 534 |
16 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2856 |
15 |
| Yang Sheng Tang Company Limited | 56 |
14 |
| Humabs Biomed SA | 122 |
13 |
| The University of North Carolina at Chapel Hill | 2039 |
13 |
| Xencor, Inc. | 396 |
13 |
| Pontificia Universidad Catolica de Chile | 295 |
12 |
| The Rockefeller University | 572 |
12 |
| VIR Biotechnology, Inc. | 144 |
12 |
| Vanderbilt University | 1908 |
11 |
| Icahn School of Medicine at Mount Sinai | 952 |
10 |
| Molecular Templates, Inc. | 71 |
10 |
| F. Hoffmann-La Roche AG | 7920 |
9 |
| Autres propriétaires | 1121 |